Treatment of Relapsed/Refractory Acute Myeloid Leukemia (Q39175665)

9 September 2017

title

Treatment of Relapsed/Refractory Acute Myeloid Leukemia (English)

1 reference

9 September 2017

1 reference

3

Jorge E Cortes

1 reference

9 September 2017

Prithviraj Bose

1

1 reference

9 September 2017

Pankit Vachhani

series ordinal

2

1 reference

9 September 2017

publication date

1 March 2017

1 reference

Current Treatment Options in Oncology

9 September 2017

published in

1 reference

9 September 2017

volume

18

1 reference

9 September 2017

issue

3

1 reference

9 September 2017

page(s)

17

1 reference

9 September 2017

cites work

Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

How I treat acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

The myth of the second remission of acute leukemia in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Orphan drug designation for pracinostat, volasertib and alvocidib in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

BET domain co-regulators in obesity, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Targeting epigenetic readers in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

FLT3 as a therapeutic target in AML: still challenging after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Impaired von Willebrand factor adhesion and platelet response in thrombospondin-2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Crenolanib is a selective type I pan-FLT3 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Emerging therapeutic drugs for AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Will targeting Chk1 have a role in the future of cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-017-0456-2

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration

21 January 2018

1 reference

12 December 2020

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.

1 reference

12 December 2020

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia

1 reference

12 December 2020

Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial

1 reference

12 December 2020

10.1007/S11864-017-0456-2

Identifiers

DOI

1 reference

9 September 2017

1 reference